MDGL - CIK 0001157601
MADRIGAL PHARMACEUTICALS, INC. trades as MDGL and has a market capitalization of $10.87 B, making it the #898 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $958.40M, up 432.1% from the prior year and net income of -$288.28M. This page tracks MADRIGAL PHARMACEUTICALS, INC. through 1,184 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 13 fiscal years MADRIGAL PHARMACEUTICALS, INC.'s revenue grew from $147.00K to $958.40M, a compound annual growth rate of 96.5%.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Major company event | 8-K | 2026-04-28 |
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Madrigal Pharmaceuticals, Inc.
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk | Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates | Madrigal Pharmaceuticals, Inc.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The largest companies sharing MADRIGAL PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a market capitalization of $10.87 B as of 2026-06-10, ranking #898 among US-listed companies.
MADRIGAL PHARMACEUTICALS, INC. reported revenue of $958.40M for fiscal year 2025, an increase of 432.1% year over year.
In its latest fiscal year MADRIGAL PHARMACEUTICALS, INC. reported a net loss of $288.28M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.